連続バイオプロセスの世界市場 (製品別、プロセス別、用途別、運用規模別、エンドユーザー別)：将来予測 (2025～2030年)

連続バイオプロセス市場は、2023年に2億3,344万米ドルと評価され、2024年には2億8,242万米ドルに達すると予測され、CAGR 21.30%で成長し、2030年には9億223万米ドルに達すると予測されています。

連続バイオプロセスは、バイオテクノロジーと医薬品産業における先進的な製造アプローチを表しており、連続フローとフィードバック制御システムを統合することで、効率、生産量、費用対効果の向上を目指しています。伝統的にバッチ処理に依存してきた業界は、モノクローナル抗体や組換えタンパク質を含む生物製剤製造において、連続バイオプロセスの強固なアプリケーションの必要性を指摘しています。その使用は、品質を維持し、生産期間を短縮しながら、生物製剤の需要増に対応するために不可欠です。最終用途の範囲は、製薬会社、受託製造機関、バイオ医薬品研究施設に及ぶ。

市場成長は、生物製剤の需要増加、より効率的で柔軟な製造プロセスの必要性、シングルユース技術や自動化における技術進歩などの要因によって顕著な影響を受ける。連続バイオプロセスが拡張性と適応性を提供できる個別化医療とバイオシミラー医薬品の台頭が主な機会となっています。企業は、生産の俊敏性を高めるために、バッチ処理と連続処理の両方を組み合わせたハイブリッドモデルの開発に投資することが推奨されます。

しかし、この市場は、高い初期設定コスト、規制上の課題、熟練した専門家の不足などの限界に直面しています。こうした要因は、中小企業がこうした技術を採用することを躊躇させる可能性があります。さらに、プロセスの標準化と検証には多大な労力と投資が必要となります。

連続バイオプロセスにおけるイノベーションは、品質管理のためのプロセス分析技術（PAT）とリアルタイムモニタリングの強化に焦点を当てることができます。堅牢でスケーラブルなシングルユースシステムと、完全に統合された連続的な下流処理モジュールの開発は、運用コストと環境への影響を大幅に削減できる研究開発の機が熟している分野です。さらに、規制経路を合理化し、技術の受容を加速するためには、業界リーダー、学術機関、規制機関の協力が不可欠です。全体として、連続バイオプロセス市場はダイナミックであり、大幅な成長の可能性を秘めているため、企業は既存の障害を乗り越えながら、新たな動向を活用するために研究開発やパートナーシップに戦略的に投資することが求められています。

市場力学：急速に進化する連続バイオプロセス市場の主要市場インサイトを公開

連続バイオプロセス市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • バイオ医薬品の需要拡大と政府による産業支援
  • バッチ処理とシングルユース技術による利点の増加
  • インダストリー4.0の到来と自動化・デジタル化の動向
• 市場抑制要因
  • 連続バイオプロセスに関する厳しい規制と高い設備コスト
• 市場機会
  • シングルユース機器に関連した灌流の採用
  • 間質細胞製造への連続バイオプロセスアプローチの開発
• 市場の課題
  • 操作上の困難とプロセス変更に関する問題

ポーターのファイブフォース：連続バイオプロセス市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：連続バイオプロセス市場における外部からの影響の把握

外部マクロ環境要因は、連続バイオプロセス市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：連続バイオプロセス市場における競合情勢の把握

連続バイオプロセス市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：連続バイオプロセス市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、連続バイオプロセス市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：連続バイオプロセス市場における成功への道筋を描く

連続バイオプロセス市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

当レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1. 市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2. 市場の発展度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3. 市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4. 競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5. 製品開発・イノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1. 現在の市場規模と今後の成長予測は？

2. 最高の投資機会を提供する製品、セグメント、地域はどこか？

3. 市場を形成する主な技術動向と規制の影響とは？

4. 主要ベンダーの市場シェアと競合ポジションは？

5. ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序論

第2章 分析手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • バイオ医薬品の需要増加と業界に対する政府の支援
    • バッチ処理と使い捨て技術の採用によるメリットの増加
    • インダストリー4.0の到来と自動化とデジタル化への傾向
  • 抑制要因
    • 連続バイオプロセスに対する厳しい規制と高額な設備コスト
  • 機会
    • 使い捨て機器に関連する灌流の採用
    • 間質細胞製造向け連続バイオプロセスアプローチの開発
  • 課題
    • 運用上の困難とプロセスの変更に関する問題
• 市場セグメンテーション分析
  • 製品：組み換えタンパク質の大規模生産におけるバイオリアクターの好感度の高まり
  • プロセス：効率性と容量の進歩により上流プロセスの使用が増加
  • 用途：ワクチン産業における連続バイオプロセスの広範な活用による公衆衛生の向上
  • 運用規模：臨床業務における連続バイオプロセスの適用拡大
  • エンドユーザー：CDMOでは柔軟性と顧客向けサービス強化を優先するため、連続バイオプロセスが重要な役割を果たします。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的要因
  • 経済的要因
  • 社会的要因
  • 技術的要因
  • 法的要因
  • 環境的要因

第6章 連続バイオプロセス市場：製品別

• バイオリアクター
• 細胞培養培地および試薬
• 遠心分離機
• クロマトグラフィーシステム
• 濾過システム
• インキュベーターとシェーカー

第7章 連続バイオプロセス市場：プロセス別

• 下流工程バイオプロセス
• 上流工程バイオプロセス

第8章 連続バイオプロセス市場：用途別

• 細胞・遺伝子治療
• モノクローナル抗体
• ワクチン

第9章 連続バイオプロセス市場：運用規模別

• 臨床運用
• 商業運用

第10章 連続バイオプロセス市場：エンドユーザー別

• 学術調査機関
• 契約開発および製造組織
• 製薬・バイオテクノロジー企業

第11章 南北アメリカの連続バイオプロセス市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の連続バイオプロセス市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの連続バイオプロセス市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析 (2023年)
• FPNVポジショニングマトリックス (2023年)
• 競合シナリオ分析
  • WuXi Biologicsは、パイロット規模で画期的な生産性約6 g/L/日を実現する完全統合型連続プロセスの導入に成功しました。
  • ザルトリウスとレプリゲンが統合バイオリアクターシステムを発売
  • 3M、バイオ医薬品濾過技術の能力向上に約1億5,000万米ドルを投資
• 戦略分析と提言

企業一覧

• 3D Biotek LLC
• 3M Company
• Adolf Kuhner AG
• bbi-biotech GmbH
• Belach Bioteknik AB
• Bio-Rad Laboratories, Inc.
• Bionet Servicios Tecnicos S.L.
• Colder Products Company
• Danaher Corporation
• Esco Aster Pte Ltd.
• Esco VacciXcell
• FiberCell Systems Inc.
• Fujifilm Holdings Corporation
• GE HealthCare Technologies Inc.
• GEA Group
• Getinge AB
• Infors AG
• Merck KGaA
• Repligen Corporation
• Sartorius AG
• simAbs NV
• Suzhou Transcenta Therapeutics Co., Ltd.
• Thermo Fisher Scientific Inc.
• Watson-Marlow Fluid Technology Group
• WuXi Biologics Co., Ltd.

LIST OF FIGURES

• FIGURE 1. CONTINUOUS BIOPROCESSING MARKET RESEARCH PROCESS
• FIGURE 2. CONTINUOUS BIOPROCESSING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. CONTINUOUS BIOPROCESSING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. CONTINUOUS BIOPROCESSING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CONTINUOUS BIOPROCESSING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CONTINUOUS BIOPROCESSING MARKET DYNAMICS
• TABLE 7. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL CULTURE MEDIA & REAGENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CENTRIFUGES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CHROMATOGRAPHY SYSTEM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY INCUBATORS & SHAKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY DOWNSTREAM BIOPROCESS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY UPSTREAM BIOPROCESS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CLINICAL OPERATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY COMMERCIAL OPERATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 46. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 48. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 73. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 75. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 78. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 80. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 163. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 164. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 166. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. POLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 183. POLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 184. POLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. POLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 186. POLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. QATAR CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 188. QATAR CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 189. QATAR CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. QATAR CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 191. QATAR CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. CONTINUOUS BIOPROCESSING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 238. CONTINUOUS BIOPROCESSING MARKET, FPNV POSITIONING MATRIX, 2023

The Continuous Bioprocessing Market was valued at USD 233.44 million in 2023, expected to reach USD 282.42 million in 2024, and is projected to grow at a CAGR of 21.30%, to USD 902.23 million by 2030.

Continuous bioprocessing represents an advanced manufacturing approach within the biotechnology and pharmaceuticals industries, aiming to improve efficiency, production yield, and cost-effectiveness by integrating continuous flow and feedback control systems. Traditionally reliant on batch processing, the industry has noted the necessity for continuous bioprocessing due to its robust application in biologics manufacturing, including monoclonal antibodies and recombinant proteins. Its use is critical in meeting growing demand for biologics while maintaining quality and reducing production timelines. The end-use scope spans pharmaceutical companies, contract manufacturing organizations, and biopharmaceutical research facilities.

Market growth is notably influenced by factors such as increasing demand for biologics, the need for more efficient and flexible manufacturing processes, and technological advancements in single-use technologies and automation. Key opportunities arise from the rise of personalized medicine and biosimilar drugs, where continuous bioprocessing can provide scalability and adaptability. Companies are encouraged to invest in developing hybrid models combining both batch and continuous processing for enhanced production agility.

However, the market faces limitations, including high initial setup costs, regulatory challenges, and a lack of skilled professionals. These factors can deter small and mid-sized enterprises from adopting these technologies. Additionally, standardization and validation of processes require significant effort and investment.

Innovations in continuous bioprocessing could focus on enhancing process analytical technology (PAT) and real-time monitoring for quality control. Development of robust and scalable single-use systems and fully integrated continuous downstream processing modules are areas ripe for research and development that could significantly reduce operational costs and environmental impact. Furthermore, collaboration between industry leaders, academic institutions, and regulatory bodies is crucial to streamline regulatory pathways and accelerate technology acceptance. Overall, the market for continuous bioprocessing is dynamic and holds substantial growth potential, inviting companies to strategically invest in R&D and partnerships to capitalize on emerging trends while navigating existing obstacles.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Continuous Bioprocessing Market

The Continuous Bioprocessing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing demand for biopharmaceuticals & government support for the industry
  • Increased benefits over batch processing & uptake of single-use technology
  • Advent of industry 4.0 & trend towards automation & digitization
• Market Restraints
  • Strict regulations for continuous bioprocessing coupled with high equipment cost
• Market Opportunities
  • Adoption of perfusion associated with single-use equipment
  • Development of a continuous bioprocessing approach to stromal cell manufacturing
• Market Challenges
  • Issues with operational difficulties and process changes

Porter's Five Forces: A Strategic Tool for Navigating the Continuous Bioprocessing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Continuous Bioprocessing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Continuous Bioprocessing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Continuous Bioprocessing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Continuous Bioprocessing Market

A detailed market share analysis in the Continuous Bioprocessing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Continuous Bioprocessing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Continuous Bioprocessing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Continuous Bioprocessing Market

A strategic analysis of the Continuous Bioprocessing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Continuous Bioprocessing Market, highlighting leading vendors and their innovative profiles. These include 3D Biotek LLC, 3M Company, Adolf Kuhner AG, bbi-biotech GmbH, Belach Bioteknik AB, Bio-Rad Laboratories, Inc., Bionet Servicios Tecnicos S.L., Colder Products Company, Danaher Corporation, Esco Aster Pte Ltd., Esco VacciXcell, FiberCell Systems Inc., Fujifilm Holdings Corporation, GE HealthCare Technologies Inc., GEA Group, Getinge AB, Infors AG, Merck KGaA, Repligen Corporation, Sartorius AG, simAbs NV, Suzhou Transcenta Therapeutics Co., Ltd., Thermo Fisher Scientific Inc., Watson-Marlow Fluid Technology Group, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Continuous Bioprocessing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Bioreactors, Cell Culture Media & Reagent, Centrifuges, Chromatography System, Filtration Systems, and Incubators & Shakers.
• Based on Process, market is studied across Downstream Bioprocess and Upstream Bioprocess.
• Based on Application, market is studied across Cell & Gene Therapy, Monoclonal Antibodies, and Vaccines.
• Based on Scale of Operation, market is studied across Clinical Operations and Commercial Operations.
• Based on End-User, market is studied across Academic & Research Institutes, Contract Development & Manufacturing Organizations, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing demand for biopharmaceuticals & government support for the industry
    • 5.1.1.2. Increased benefits over batch processing & uptake of single-use technology
    • 5.1.1.3. Advent of industry 4.0 & trend towards automation & digitization
  • 5.1.2. Restraints
    • 5.1.2.1. Strict regulations for continuous bioprocessing coupled with high equipment cost
  • 5.1.3. Opportunities
    • 5.1.3.1. Adoption of perfusion associated with single-use equipment
    • 5.1.3.2. Development of a continuous bioprocessing approach to stromal cell manufacturing
  • 5.1.4. Challenges
    • 5.1.4.1. Issues with operational difficulties and process changes
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Growing preference for bioreactors in large-scale production of recombinant proteins
  • 5.2.2. Process: Rising usage of upstream processes owing to progress in terms of efficiency and capacity
  • 5.2.3. Application: Extensive utilization of continuous bioprocessing in the vaccine industry to improve public health
  • 5.2.4. Scale of Operation: Growing application of continuous bioprocessing in the clinical operations
  • 5.2.5. End-User: Significant role of continuous bioprocessing in CDMO as they prioritize flexibility and service offering enhancements for their clients
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Continuous Bioprocessing Market, by Product

• 6.1. Introduction
• 6.2. Bioreactors
• 6.3. Cell Culture Media & Reagent
• 6.4. Centrifuges
• 6.5. Chromatography System
• 6.6. Filtration Systems
• 6.7. Incubators & Shakers

7. Continuous Bioprocessing Market, by Process

• 7.1. Introduction
• 7.2. Downstream Bioprocess
• 7.3. Upstream Bioprocess

8. Continuous Bioprocessing Market, by Application

• 8.1. Introduction
• 8.2. Cell & Gene Therapy
• 8.3. Monoclonal Antibodies
• 8.4. Vaccines

9. Continuous Bioprocessing Market, by Scale of Operation

• 9.1. Introduction
• 9.2. Clinical Operations
• 9.3. Commercial Operations

10. Continuous Bioprocessing Market, by End-User

• 10.1. Introduction
• 10.2. Academic & Research Institutes
• 10.3. Contract Development & Manufacturing Organizations
• 10.4. Pharmaceutical & Biotechnology Companies

11. Americas Continuous Bioprocessing Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Continuous Bioprocessing Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Continuous Bioprocessing Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
  • 14.3.2. Sartorius and Repligen Launch Integrated Bioreactor System
  • 14.3.3. 3M To Invest Nearly USD 150 Million To Advance Capabilities In Biopharma Filtration Technology
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 3D Biotek LLC
• 2. 3M Company
• 3. Adolf Kuhner AG
• 4. bbi-biotech GmbH
• 5. Belach Bioteknik AB
• 6. Bio-Rad Laboratories, Inc.
• 7. Bionet Servicios Tecnicos S.L.
• 8. Colder Products Company
• 9. Danaher Corporation
• 10. Esco Aster Pte Ltd.
• 11. Esco VacciXcell
• 12. FiberCell Systems Inc.
• 13. Fujifilm Holdings Corporation
• 14. GE HealthCare Technologies Inc.
• 15. GEA Group
• 16. Getinge AB
• 17. Infors AG
• 18. Merck KGaA
• 19. Repligen Corporation
• 20. Sartorius AG
• 21. simAbs NV
• 22. Suzhou Transcenta Therapeutics Co., Ltd.
• 23. Thermo Fisher Scientific Inc.
• 24. Watson-Marlow Fluid Technology Group
• 25. WuXi Biologics Co., Ltd.